Denfivontinib is under clinical development by Genosco and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Denfivontinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Denfivontinib overview

Denfivontinib (SKI-G-801) is under development for the treatment of advanced solid cancer, relapsed or refractory acute myeloid leukemia. The drug candidate targets FMS-like tyrosine kinase 3  (FLT3) and AXL. It is administered through intravenous route.

Genosco overview

Genosco. (Genosco), a subsidiary of Oscotec Inc, is a clinical-stage biotech company that specializes in the discovery and development of novel kinase inhibitors. The company’s main activities revolve around the use of its proprietary G-SMART platform, which enables the identification of rare sequences and the rapid generation of highly selective compounds. Genosco’s product pipeline includes multiple independent and partnered pipelines, which focus on kinase-targeted therapies. The company’s products are primarily designed for patients with unmet medical needs, particularly in the field of precision medicine. It operates primarily in the Boston area, its products are intended for a global market. Genosco is headquartered in Billerica, Massachusetts, the US.

For a complete picture of Denfivontinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.